Drug Database
PE

pegfilgrastim (Armlupeg)

✓ Approved

Lupin Limited · CSF3R · 重组蛋白

什么是 pegfilgrastim?

pegfilgrastim 是一种重组蛋白,由Lupin Limited研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名Armlupeg
公司Lupin Limited
药物类别重组蛋白
分子靶点CSF3R
给药途径Unknown
状态Approved

作用机制

分子靶点

pegfilgrastim 作用于 1 个分子靶点:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pegfilgrastim 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersBone marrow disorder✓ Approved

相关研究文献

PubMedTransplantation and cellular therapy2026-11-15

Comparison of pegfilgrastim and daily G-CSF for CD34+ cell mobilization in healthy donors and post-transplant engraftment: The Pegfilgrastim-23 Study.

Hatase Masanao M, Goto Hideki H, Shimizu Hiroaki H, Toya Takashi T et al.

Pegfilgrastim (Peg-G), a long-acting formulation of granulocyte colony-stimulating factor (G-CSF), enables single-dose administration and effectively mobilizes CD34+ cells into the peripheral blood of healthy donors undergoing allogeneic hematopoietic stem cell transplantation. However, prospective comparisons with conventional daily G-CSF (Daily-G) regarding mobilization efficacy and safety remain limited. Moreover, no previous studies have compared the differentiation profiles of CD34+ cells mobilized by these two agents. In this multicenter, prospective observational study, we assessed the efficacy, kinetics, safety and differentiation profiles of mobilized CD34+ cells induced by either 7.2 mg dose of Peg-G on day 1 (n = 29) or Daily-G at 400 μg/m2/day from day 1 (n = 31) in 60 healthy related donors scheduled to undergo CD34+ cell collection. Hematopoietic engraftment was also evaluated in 60 recipients following infusion of the collected peripheral blood stem cells. Of the 60 enrolled donors, 50 were evaluable for peripheral blood CD34+ cell counts. The mean CD34+ cell counts were 85.6 ± 48.0 × 10⁶/L in the Peg-G group and 84.6 ± 42.4 × 10⁶/L in the Daily-G group, with no significant difference between the groups (P = .992). Similar findings were observed in the analyses stratified by collection on days 4 and day 5. No significant differences were observed in the differentiation profiles of mobilized CD34⁺ cells. The kinetics of peripheral blood cell counts were generally comparable between the groups in both the day 4 and day 5 collection cohorts, except for a higher white blood cell count on day 4 in the Peg-G group among donors collected on day 5. In exploratory analyses, CD34⁺ cell mobilization efficacy was not correlated with day 4 serum G-CSF concentrations, donor age, body weight, body mass index, or body surface area in either of the treatment groups. Adverse events were common but predominantly consisted of pain-related symptoms that were manageable with supportive care. Grade 3 adverse events included liver dysfunction in three donors and hypertension in one. All laboratory abnormalities and clinical symptoms resolved by the follow-up assessment, and no grade ≥4 adverse events were observed in any donor. Median times to neutrophil engraftment were 16 and 15 days in the Peg-G and Daily-G groups, respectively (P = .73), and those to platelet engraftment were 30 and 27 days, respectively (P = .68). Single-dose 7.2-mg Peg-G and conventional Daily-G resulted in comparable peripheral blood CD34⁺ cell mobilization and differentiation profiles of mobilized CD34⁺ cells in healthy related donors, with generally manageable safety profiles. No significant differences in the time to neutrophil or platelet engraftment were observed between recipients in the two groups. These findings suggest that both mobilization strategies are clinically applicable and that regimen selection may be tailored according to drug-specific characteristics and donor convenience.

PMID 43033915
阅读全文 →
PubMedThe Tohoku journal of experimental medicine2026-11-05

Omission of Pegfilgrastim in Perioperative Dose-Dense Paclitaxel Therapy for Breast Cancer.

Otake Kaori K, Morikawa Naoto N, Kurihara Makoto M, Kumagai Fumiyoshi F et al.

PMID 42983787
阅读全文 →
PubMediScience2026-10-19

A phase 3 trial of GB-K02 pegfilgrastim biosimilar for preventing chemotherapy-induced neutropenia in breast cancer.

Lin Jinhai J, Peng Hengxin H, Zhang Yijia Y, Yi Yufang Y et al.

Chemotherapy-induced neutropenia (CIN) constitutes a substantial disease burden globally. Although pegfilgrastim (a long-acting granulocyte-colony stimulating factor) has demonstrated efficacy in preventing CIN, it is not yet available in China. This is the first clinical study to evaluate a pegfilgrastim biosimilar in China. This multicenter, randomized, double-blind, parallel-controlled, phase 3 equivalence study aims to evaluate the efficacy and safety of GB-K02 (a pegfilgrastim biosimilar) in preventing CIN among 250 patients with breast cancer. The primary efficacy endpoint was the duration of grade 4 neutropenia (DG4N) in cycle 1 of chemotherapy. The DG4N (LSMean ± SE) in cycle 1 was 0.58 ± 0.13 days versus 0.80 ± 0.13 days (p = 0.2139) for the GB-K02 group and the pegfilgrastim group, respectively. Other efficacy endpoints and safety were also similar between the two groups in 4 cycles of chemotherapy. Overall, GB-K02 demonstrated proper equivalence to pegfilgrastim and might offer an option in preventing CIN in China.

PMID 42894857
阅读全文 →
PubMedJCO oncology practice2026-10-06

Impact of Primary Prophylactic Colony-Stimulating Factor Delivery Method on Febrile Neutropenia: Secondary Analysis of a Pragmatic Cluster Randomized Clinical Trial.

Shih Lauren L, Arnold Kathryn B KB, Bansal Aasthaa A, Bell-Brown Ari A et al.

Primary prophylactic colony-stimulating factor (PP-CSF) is recommended for patients receiving chemotherapy with high risk of febrile neutropenia (FN). The impact of PP-CSF delivery method on FN is unknown. We performed a secondary analysis of SWOG S1415CD (Trial Assessing CSF Prescribing Effectiveness and Risk), a pragmatic, cluster-randomized trial evaluating a guideline-informed standing order system to improve PP-CSF use, to evaluate associations between PP-CSF delivery method and FN. Female patients with breast cancer receiving first-line chemotherapy and PP-CSF with a known delivery method (administration in-clinic [IC], home delivery via an on-body device [OBD], or home self-injection [SI]) were included. The primary outcome was FN within 6 months of chemotherapy initiation, defined per the Common Terminology Criteria for Adverse Events. Among 1,713 patients, the median age was 55 years (IQR, 46-64). By stage, 566 (33%) were local, 709 (41%) regional, 41 (2%) distant, and 397 (23%) unknown. PP-CSF was delivered IC in 773 (45%), OBD in 862 (50%), and SI in 78 (5%). Most received high-risk FN regimens. Pegfilgrastim use was nearly exclusive in IC and OBD (98% and 99%), versus 29% in SI. FN incidence was low: IC 3.8% (95% CI, 2.5 to 5.3), OBD 5.0% (95% CI, 3.6 to 6.6), and SI 6.4% (95% CI, 2.1 to 14.3; P = .29). FN was associated with high-risk FN regimens (odds ratio [OR], 2.97 [95% CI, 1.2 to 9.9]; P = .04) and Zubrod performance status ≥2 (OR, 4.99 [95% CI, 1.12 to 15.9]; P = .01), but not with delivery method or PP-CSF agent. Women with breast cancer receiving chemotherapy and PP-CSF had low rates of FN regardless of PP-CSF delivery method or agent. Delivery decisions may be guided by patient-centered factors including cost, convenience, and access.

PMID 42837634
阅读全文 →
PubMedRhode Island medical journal (2013)2026-09-25

Atypical Bullous Sweet Syndrome.

London Jonathan J, Patresan John J, Belkin Alexander A, Elnair Radowan R

Sweet syndrome (acute febrile neutrophilic dermatosis) is characterized by fever, leukocytosis, and tender erythematous skin lesions with neutrophilic infiltrate. Although associated with granulocyte colony-stimulating factor (G-CSF) use, its occurrence with pegfilgrastim-the pegylated form-is rare, with fewer than five reported cases. Sweet syndrome has also been rarely linked to FLT3 inhibitors such as quizartinib. We report a 71-year-old male with acute myeloid leukemia who developed bullous Sweet syndrome following concurrent exposure to pegfilgrastim and quizartinib.

PMID 42789806
阅读全文 →
PubMedEuropean journal of cancer (Oxford, England : 1990)2026-09-25

Prophylactic use of G-CSFs to reduce neutropenia rates in patients treated with antibody-drug conjugates: A literature review.

Scotté Florian F, Lustberg Maryam M, Aapro Matti M, Ben Abid Fatma F et al.

Although multiple antibody-drug conjugates (ADCs) have demonstrated sufficient efficacy and safety to warrant their approval, many patients require supportive treatment to reduce the severity of ADC-associated toxicities. Clinical guidelines recommend the use of granulocyte colony-stimulating factors (G‑CSFs), such as filgrastim, lenograstim, and long-acting pegfilgrastim, to reduce the duration and severity of chemotherapy-induced neutropenia and the risk of febrile neutropenia (FN). The objective of this literature review was to summarize the available data on the use of G-CSFs in patients treated with ADCs as a strategy to mitigate the risk of severe neutropenia and FN. The identified literature highlight the importance of prophylactic G-CSF use to reduce the occurrence of FN and severe neutropenia in patients treated with ADCs. Although data evaluating the effect of G-CSF use as secondary prophylaxis are limited, available studies highlight the clinical necessity of mitigating neutropenia risk associated with ADCs.

PMID 42790204
阅读全文 →

注册免费账户还可查看另外 1076 篇文献

免费注册查看全部文献 →

了解更多pegfilgrastim